Intesa Sanpaolo rebalanced its crypto-related ETF holdings for the quarter ended June 30, sharply reducing exposure tied to the iShares Bitcoin Trust ETF. The underlying-share amount for its IBIT call position fell 99.3% and its IBIT common-share holding dropped 93.7%, while its iShares Staked Ethereum Trust ETF position rose to 349,600 shares, slightly more than tripling. It also nearly exited the Bitwise Solana Staking ETF and kept its Grayscale XRP Trust ETF position unchanged. The changes were disclosed in the bank’s U.S. SEC Form 13F filing.

Nasdaq-listed Chinese insurtech Zhibao Technology has signed a $154.7 million PIPE agreement payable in 2,380 BTC. The deal calls for the sale of 442 million units at $0.35 each, with warrants that could lift total new issuance to 884 million Class A shares and drive substantial dilution. The governance terms would allow the investor group to name four of five directors and install a new CEO and CFO, raising the risk that the current leadership is sidelined. The announcement has weighed on the stock, but the report did not provide the company’s ticker symbol.

Interactive Strength paid a dividend on July 28 in the form of 619,584 preferred shares, creating about $1.239 million of additional minimum base liquidation preference that ranks ahead of common stockholders. Series A preferred shares rose 6.37% and carry an 8% cumulative annual dividend, while Series C increased 11.87% with a 15% annual dividend and higher liquidation priority than Series A, Series B and common shares. The move preserved cash but increased preferred liquidation claims, reducing common shareholders’ position and potential recovery in a bankruptcy or liquidation scenario.

Lite Strategy, a Nasdaq-listed company that uses Litecoin (LTC) as its primary reserve asset, spent about $5.4 million to repurchase roughly 4.9 million common shares through July 17, equal to about 13% of the shares outstanding when the program began, without adding debt. The buyback reduced the company’s reported Litecoin holdings, but LTC backing per outstanding common share rose by about 1.7%. The transaction was funded using an undisclosed mix of LTC sales and covered-call premiums, and it involved no traditional financial assets.

Stablecoin Development Corporation (SDEV) said it generated about $2.2 million in second-quarter staking revenue from Sky Protocol’s SKY token, roughly matching what it described as cash operating expenses. Over the same period, the company recorded a $50.6 million unrealized, noncash loss on digital assets, contributing to a $53.8 million operating loss and a $41.1 million net loss. The filing also highlighted potential share dilution tied to prefunded warrants, with one tranche permitting exercise for up to about 33.5 million shares. The company’s balance sheet remained heavily concentrated in SKY holdings.

Dogecoin Ventures, a wholly owned unit of House of Doge, borrowed $1.4 million from Devlin DeFrancesco under an unsecured note issued on July 28 that carries 10.7% annual interest and matures July 27, 2027. The company agreed to repay principal by delivering 2,227,300 shares of CleanCore Solutions rather than cash, while paying interest in cash. The shares designated for repayment are already pledged to House of Doge’s senior lenders, placing the new note behind secured creditors in the payment order.

SOS Limited (SUS) has come under pressure over its ability to sustain operations after pausing direct cryptocurrency mining, ending 2025 with $3.232 million in cash and reporting a $97.3 million net loss along with a $5.8 million mining-equipment impairment. Shareholders approved a 100-fold increase in authorized shares on July 27, clearing the way for potential large-scale equity fundraising. If carried out through future issuances, the move would significantly dilute existing shareholders.

Nasdaq-listed biotech Enlivex (ENLVX) is asking shareholders to authorize up to $800 million in financing, largely to be paid in its self-developed RAIN crypto token, a structure that could increase its ordinary share count by as much as 951%. Only up to 5% of remaining USD proceeds could be used to fund development of its core drug, Allocetra. The proposal implies heavy dilution for existing shareholders and directs most proceeds away from the company’s main biotech business, raising questions about governance and R&D sustainability.

A public company reported an $8.32 billion unrealized loss on its Bitcoin holdings, leading to an $8.22 billion net loss in the second quarter. Its BTC holdings rose to 846,000 BTC by quarter-end, then slipped to 843,775 BTC after a small sale to meet preferred-stock obligations. Over the first seven months of 2026, it net-added more than 170,000 BTC. The figures focus solely on Bitcoin holdings and related gains and losses, with no changes cited for traditional financial assets such as stocks, bonds, commodities or indexes.